Dr. Ehab Elnakouri
panellist
Professor clinicial Oncology Cairo university
Saudi German hospital Jeddah oncology dept head
16:45-17:30
Friday 3-5-2024 Day 1
Transition from hormonal-based to chemotherapy in metastatic BC??
- Patients with early progression on CDK4-6 inhibitors: What is next??
- When to start ADCs/olaparib in patients who had visceral crisis?? Can be upfront??
- Any role of hormonal monotherapy after CDK4-6 inhibitors??
- Biomarkers to guide subsequent therapies
- Can we use one ADC after previous ADC??
Moderator: 
Dr. Ahmed Alfaraj
Panel:
